Radiobiology

JCRI-ABTS and USMI Successfully Complete Phase 1 Multi-Center Clinical Trial Using Canady Helios™ Cold Plasma for the Treatment of Cancer

Retrieved on: 
Tuesday, April 20, 2021
Science, Biotechnology, Research, Surgery, Oncology, Health, Medical devices, Clinical trials, Spacecraft, Spaceflight, Medical physics, Radiobiology, Canady, Radiation therapy, Helios, Physical sciences, JCRI-ABTS, US Medical Innovations, JCRI-ABTS, US MEDICAL INNOVATIONS

b'The Jerome Canady Research Institute for Advanced Biological and Technological Sciences, LLC (JCRI-ABTS) and US Medical Innovations, LLC (USMI) announced today that they have successfully completed Phase 1 in their Clinical Trial using Canady Helios\xe2\x84\xa2 Cold Plasma (CHCP) for the treatment of recurrent and stage 4 solid tumors (IDE #G190195).

Key Points: 
  • b'The Jerome Canady Research Institute for Advanced Biological and Technological Sciences, LLC (JCRI-ABTS) and US Medical Innovations, LLC (USMI) announced today that they have successfully completed Phase 1 in their Clinical Trial using Canady Helios\xe2\x84\xa2 Cold Plasma (CHCP) for the treatment of recurrent and stage 4 solid tumors (IDE #G190195).
  • This novel non-thermal process (24-27o C) has been developed for treating solid cancerous tumors.
  • Canady continued, \xe2\x80\x9cUnlike Chemo and Radiation Therapy, the Canady Helios\xe2\x84\xa2 Cold Plasma Therapy has many advantages.
  • It is highly selective because it only targets cancer cells without damaging surrounding healthy tissue.

On Earth Day, Protecting the Environment With UV Technology

Retrieved on: 
Tuesday, April 20, 2021
Hygiene, Ultraviolet radiation, Electromagnetic radiation, Medical specialties, Radiation, Water treatment, Radiobiology, Sterilization, Ultraviolet germicidal irradiation, Ultraviolet, Disinfectant, Light-emitting diode

"Incorporating ultraviolet light technology into your disinfection protocols can reduce the frequency of use of chemical cleaners and provides a sustainable alternative for keeping public spaces disinfected.

Key Points: 
  • "Incorporating ultraviolet light technology into your disinfection protocols can reduce the frequency of use of chemical cleaners and provides a sustainable alternative for keeping public spaces disinfected.
  • "It presents a sustainable, practical, alternative approach to chemicals to produce clean spaces in smart, healthy buildings while also protecting our environment.
  • "\nViolet Defense uses UV disinfection to protect everyday spaces from harmful pathogens by killing up to 99.9% of E. coli, Salmonella, MRSA, C.
  • Violet Defense\'s technology is the only known Pulsed Xenon solution that can be installed into a room full-time, creating a continuous way to address disinfection needs of all types of settings.

ASG Superconductors with HZDR combine magnetic resonance imaging with proton therapy

Retrieved on: 
Monday, April 19, 2021
Physical sciences, Physics, Natural sciences, Medical physics, Helmholtz-Zentrum Dresden-Rossendorf, Radiobiology, Proton therapy, Magnetic resonance imaging, Linear particle accelerator, Radiation therapy, Superconductivity

b'GENOA, Italy, April 19, 2021 /PRNewswire/ -- ASG Superconductors with Helmholtz-Zentrum Dresden-Rossendorf (HZDR) will build the world\'s first prototype that tracks moving tumors with magnetic resonance imaging (MRI) in real time during proton therapy, combining a rotating open MRI device for the LINAC-MR system Alberta Health Services, with an actively scanned clinical-akin proton beam at OncoRay, the Dresden-based National Center for Radiation Research in Oncology.

Key Points: 
  • b'GENOA, Italy, April 19, 2021 /PRNewswire/ -- ASG Superconductors with Helmholtz-Zentrum Dresden-Rossendorf (HZDR) will build the world\'s first prototype that tracks moving tumors with magnetic resonance imaging (MRI) in real time during proton therapy, combining a rotating open MRI device for the LINAC-MR system Alberta Health Services, with an actively scanned clinical-akin proton beam at OncoRay, the Dresden-based National Center for Radiation Research in Oncology.
  • The rotating MRI device is produced by ASG Superconductors, using the MROpen Evo technology-based helium-free superconducting MgB2 magnet.
  • Real-time MRI would make it possible to synchronize the proton beam to tumor motion during radiation dose delivery.
  • "\n"Our partnership with HZDR and ASG has been extremely positive," says Mike Cogswell, MagnetTx President and CEO.

Radiation Oncology Market Size Worth $11.7 Billion By 2028 | CAGR: 7.0%: Grand View Research, Inc.

Retrieved on: 
Monday, April 19, 2021
Radiobiology, Medical physics, Radiation therapy, Radioactivity, Oncology, Nuclear physics, Physical sciences, Medicine

b'SAN FRANCISCO, April 19, 2021 /PRNewswire/ --The global radiation oncology market size is expected to reach USD 11.7 billion by 2028, registering a CAGR of 7.0% over the forecast period, according to a new report by Grand View Research, Inc.

Key Points: 
  • b'SAN FRANCISCO, April 19, 2021 /PRNewswire/ --The global radiation oncology market size is expected to reach USD 11.7 billion by 2028, registering a CAGR of 7.0% over the forecast period, according to a new report by Grand View Research, Inc.
  • Advancement from 2D to 3D conformal radiotherapy, motion tracking, and real-time imaging has helped improve radiation targeting and thereby reduce exposure to the surrounding healthy tissues.
  • For instance, Accuray Incorporated introduced its motion monitoring and correction tools, Synchrony, for the Radixact device in April 2019.
  • Similar is the situation in other countries in the Indian sub-continent.\nGrand View Research has segmented the global radiation oncology market on the basis of type, technology, application, and region:\nRadiation Oncology Type Outlook (Revenue, USD Million, 2017 - 2028)\n'

Radiation Oncology Market Size Worth $11.7 Billion By 2028 | CAGR: 7.0%: Grand View Research, Inc.

Retrieved on: 
Monday, April 19, 2021
Radiobiology, Medical physics, Radiation therapy, Radioactivity, Oncology, Nuclear physics, Physical sciences, Medicine

b'SAN FRANCISCO, April 19, 2021 /PRNewswire/ --The global radiation oncology market size is expected to reach USD 11.7 billion by 2028, registering a CAGR of 7.0% over the forecast period, according to a new report by Grand View Research, Inc.

Key Points: 
  • b'SAN FRANCISCO, April 19, 2021 /PRNewswire/ --The global radiation oncology market size is expected to reach USD 11.7 billion by 2028, registering a CAGR of 7.0% over the forecast period, according to a new report by Grand View Research, Inc.
  • Advancement from 2D to 3D conformal radiotherapy, motion tracking, and real-time imaging has helped improve radiation targeting and thereby reduce exposure to the surrounding healthy tissues.
  • For instance, Accuray Incorporated introduced its motion monitoring and correction tools, Synchrony, for the Radixact device in April 2019.
  • Similar is the situation in other countries in the Indian sub-continent.\nGrand View Research has segmented the global radiation oncology market on the basis of type, technology, application, and region:\nRadiation Oncology Type Outlook (Revenue, USD Million, 2017 - 2028)\n'

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Retrieved on: 
Tuesday, April 13, 2021
Oncology, Medical devices, Health, Radiology, Cardiology, Biotechnology, Physical sciences, Natural sciences, Chemistry, Radiopharmaceuticals, Medicinal radiochemistry, Radioactivity, Radiobiology, Medicinal chemistry, Technetium-99m, Radiopharmacology, Isotopes of molybdenum, Northstar

b'NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.\nThis press release features multimedia.

Key Points: 
  • b'NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.\nThis press release features multimedia.
  • The new structure enables NorthStar to advance its radioisotope development and commercialization planning efforts in parallel with ongoing expansion programs for increased U.S. Mo-99 capacity and production.
  • The facility will enable NorthStar to more than double its production of Mo-99, used with RadioGenix Systems to produce Tc-99m.
  • Like other NorthStar processes, accelerator production of Mo-99 using the \xe2\x80\x9cneutron knock-out\xe2\x80\x9d method is non-uranium based and highly efficient.

Molecular Targeting Technologies, Inc. Announces a New PET Imaging Agent for Rapid Monitoring Tumor Response to Therapy

Retrieved on: 
Tuesday, April 13, 2021
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Health sciences, Medicine, Physical sciences, Medical physics, Medicinal chemistry, Medicinal radiochemistry, Radiopharmaceuticals, Radiobiology, Radiation therapy, Stroke, Therapy, Positron emission tomography

These diseases are common, but their progression and responses to therapy are still hard to track reliably.

Key Points: 
  • These diseases are common, but their progression and responses to therapy are still hard to track reliably.
  • This tracer enables use of high resolution, high sensitivity PET, to detect myocardial infarction and brain stroke.
  • It is also ideal for monitoring rapid tumor response to radiation and drug treatment.
  • The company is committed to building value by acquiring and translating innovative imaging, radiopharmaceutical therapy assets to improve human health, reduce healthcare costs and reward stakeholders.

$ 501.27 Million Growth Expected in the Global Radiation Detection and Monitoring Equipment Market 2021-2025 by Product and Geography- Technavio.com

Retrieved on: 
Thursday, April 8, 2021
Radiation protection, Particle detectors, Radiobiology, Radiation, Ionizing radiation, Medical physics, Nuclear physics

The radiation detection and monitoring equipment market is poised to grow by $ 501.27 million during 2021-2025 progressing at a CAGR of over 5%, owing to the growing demand from healthcare facilities, increasing use of radiation detection and monitoring in different industries, and regulations mandating the use of radiation detection and monitoring equipment.

Key Points: 
  • The radiation detection and monitoring equipment market is poised to grow by $ 501.27 million during 2021-2025 progressing at a CAGR of over 5%, owing to the growing demand from healthcare facilities, increasing use of radiation detection and monitoring in different industries, and regulations mandating the use of radiation detection and monitoring equipment.
  • The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
  • Our radiation detection and monitoring equipment market research report is covering the current trends and effects on the business of COVID-19.
  • Along with this, the report also provides a detailed analysis of several leading radiation detection and monitoring equipment market vendors and emerging players.

Fomo Corp. Announces Disinfection Patent and Customer Win

Retrieved on: 
Wednesday, April 7, 2021
Ultraviolet radiation, Hygiene, Radiation, Radiobiology, Sterilization, Ultraviolet germicidal irradiation, Public health, Health, Fastsigns, Articles, Disinfectant, Ultraviolet

Purge Virus - New Account:

Key Points: 
  • Purge Virus - New Account:
    Last week, Purge Virus provided the combination ionization and ultraviolet light disinfection for FASTSIGNS of Exton, PA as well as the Clean Air!
  • door signage and interior countertop signage that describes the disinfection technology.
  • This location is one of over 700 FASTSIGNS locations, and Purge Virus hopes to rollout the disinfection across the other locations.
  • Purge Virus patent centers on advanced ultraviolet germicidal irradiation (UVGI), which is part of the recent March 23, 2021 CDC guidance for COVID-19 mitigation.

Violet Defense Conducts Disinfection Evaluation With Kansas School District

Retrieved on: 
Wednesday, April 7, 2021
Ultraviolet radiation, Hygiene, Radiation, Radiobiology, Sterilization, Ultraviolet germicidal irradiation, Ultraviolet, Disinfectant

Violet Defense will provide the Ottawa school district with a variety of mobile and installed S.A.G.E.

Key Points: 
  • Violet Defense will provide the Ottawa school district with a variety of mobile and installed S.A.G.E.
  • For the evaluation, Violet Defense and the Ottawa school district will conduct side-by-side testing with one classroom and one bathroom each outfitted with Violet Defense's disinfection UV equipment, and a comparable classroom and bathroom acting as the control group.With this scientific structure, data will be able to show the effectiveness of the UV disinfection products versus natural germ progression and chemical-based cleaning methods.
  • "We are proud to support Violet Defense's work in the Ottawa Public School District Evaluation," said Ottawa Superintendent Dr. Ryan Cobbs.
  • Violet Defense uses UV disinfection to protect everyday spaces from harmful pathogens by killing up to 99.9% of E. coli, Salmonella, MRSA, C.